Decorative image

Research

Find out about the latest UK research and clinical trials looking at myeloma.

Biological therapies

Biological therapies are treatments that act on processes in cancer cells. Many types of biological therapy drugs are being tested for myeloma. Some are used as part of standard treatment.

Researchers continue to look at these drugs in different combinations and at timings of when is best to use them, as well as studying new types of biological therapy.

There is research into specific biological therapies:

  • bortezomib (Velcade)
  • vemurafenib
  • thalidomide
  • lenalidomide (Revlimid) 
  • pomalidamide
  • carfilzomib
  • monoclonal antibodies such as siltuximab
  • panobinostat 

Vaccines

Vaccines are a type of biological therapy. Myeloma vaccines are designed to try to encourage your own immune system to pick out and attack myeloma cells. 

Vaccine treatment for myeloma is very experimental, and is only available as part of a clinical trial. 

Targeted radiotherapy

Radiotherapy has been a treatment for myeloma for some time. But one of the problems with it is that the high doses that you need to kill myeloma cells affects that rest of the body. This causes side effects. Researchers are looking into how to reduce the effect on healthy cells.

Targeted radiotherapy uses a radioactive cell that is attached to a biological therapy drug, called a monoclonal antibody. The monoclonal antibody looks specifically for myeloma cells. It carries the radiation to the cancer cells. So they have a high dose of radiation and are killed but there are fewer side effects for the rest of the body. 

Chemotherapy

Chemotherapy is one of the main treatments for myeloma. Researchers are looking into combining it with biological therapies and steroids. They are also looking at combining different drugs and new chemotherapy drugs.

Research is looking at:

  • liposomal doxorubicin (Caelyx) with bortezomib (Velcade) 
  • bendamustine, thalidomide, and bortezomib (Velcade)

Stem cell transplants

Intensive treatment is when you have high dose chemotherapy followed by stem cell transplant. Having the stem cells back means that you can have the high dose chemotherapy. It has been a treatment for myeloma for some time. Doctors are researching how to minimise side effects of stem cell transplants. They also want to lengthen the time that people with myeloma are in remission. This is when there is no sign of myeloma when you have tests. They hope that they may be able to eventually cure it.

Double transplant

These are also called tandem transplants. This means having another stem cell transplant or bone marrow transplant about 6 months after your first transplant. The aim is to keep your myeloma in remission for longer. Having 2 transplants increases the risks and side effects. The research is ongoing.

Mini transplant

Mini transplants are also called reduced intensity conditioning (RIC) allografts.

Conditioning is the chemotherapy or radiotherapy you have as part of your transplant. An allograft is a transplant from another person. The other person is a matched donor. Your bone marrow must match theirs. A matched donor is often a brother or sister.

With a mini transplant you have a lower dose of chemotherapy or radiotherapy than you would with a standard transplant. You have chemotherapy but not enough to destroy your bone marrow completely. It is enough to stop you reacting to the donor cells. After the chemotherapy you have the stem cell transplant, using your donors stem cells.

You might have an infusion of your donors white blood cells (lymphocytes) if your myeloma doesn't respond, or if it comes back after transplant. This is called donor lymphocyte infusion or DLI.

Research is trying to find out if it is helpful to give extra white blood cells (lymphocytes) after a mini transplant. They want to find out if it helps to keep myeloma in remission for longer and if it reduces side effects including infections and a condition called graft versus host disease (GVHD).

Timing of transplants

We know from research that people who have a very good response to their initial chemotherapy can stay free of myeloma (be in remission) for a long time, whether or not they have a stem cell transplant. So for these people, it may be better to wait until myeloma comes back before having a transplant.

Research is looking at a combination of biological therapy (bortezomib), chemotherapy (adriamycin), and steroids (dexamethasone). This combination is called PAD. Doctors want to know if this combination means people can wait longer before needing a stem cell transplant, if their myeloma has come back. 

Treating kidney failure

People with myeloma often have kidney problems because of the high levels of protein (immunoglobulin or paraprotein) in their blood.

Some people have kidney failure when they are diagnosed. Blood is usually filtered to remove waste products by a machine. This is called dialysis, and is the standard treatment.

Treatment called plasma exchange (plasmapheresis) may help damaged kidneys to recover. Research is looking to see if plasma exchange, combined with chemotherapy and steroids can improve how the kidneys work in people with myeloma. 

Living with myeloma

Research aims to understand how quality of life is affected by different stages of myeloma. 

Current research is trying to understand if physical activity affects how people feel physically and psychologically when in remission from myeloma. Researchers are interested in how lifestyle factors affect energy levels, mood and self confidence. It might help to build rehabilitation programmes after myeloma.

Recent research studied the symptoms of advanced myeloma such as pain and tiredness. It aimed to help with new guidelines on follow up for myeloma. 

Last reviewed: 
09 Jan 2016
  • The Medical Research Council Myeloma IX trial: the impact on treatment paradigms

    P Richardon and others (2012) 

    European Journal of Haematology Jan;88(1):1-7

  • The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

    G Morgan and others (2012) 

    Blood Jan 5;119(1):7-15

Information and help

Dangoor sponsorship

About Cancer generously supported by Dangoor Education since 2010.